Warning: Creating default object from empty value in /home/pharmawa/public_html/wp-content/themes/canvas/functions/admin-hooks.php on line 160

Military Announces Clinical Trials Set For PTSD Drugs

PTSDOur country has been at war for over a decade.  Our soldiers are tired and weary, and many dealing with severe issues, such as Post Traumatic Stress Disorder (PTSD) from the things they have seen and experienced on the battlefield.

Although doctors like Dr. Elspeth Cameron Ritchie whom recently retired from the U.S. Army as a colonel and is now the chief clinical officer for the District of Columbia’s department of mental health, encourages counseling in several forms and consideration for such things as acupuncture, yoga and therapy dogs to help veterans adjust, many military and Veterans Affairs Department physicians often prescribe medication to ease the symptoms of combat-related PTSD.

But, there are only two antidepressantsPaxil and Zoloft — that are approved specifically by the Food and Drug Administration to treat the disorder.  And, little data exists on which “off-label” medications work and which don’t.

Therefore, according to recent announcements, the Army is trying to get a better handle on the very complicated issue of how drugs fit into the treatment of these traumatized veterans, with a study of the effectiveness of the drugs most often prescribed. The research will be launched next year, reports The Navy Times.

Speaking at the American Psychiatric Association meeting in Philadelphia, Army Maj. Gary Wynn of the Walter Reed Army Institute of Research and Col. David Benedik, associate director for the Center for the Study of Traumatic Stress at the Uniformed Services University of the Health Sciences announced the service will start clinical trials next year to evaluate commonly prescribed PTSD medications like the antidepressant Cymbalta, mirtazapine, prazosin and atypical antipsychotics like Seroquel. It will test hundreds of vets and service members at multiple sites over several years.

“We’re trying to advance the science to catch up with clinical practice,” Wynn said. “This effort will seek to provide clinicians with a higher level of evidence when choosing a drug.” says Army Major Wynn.

The announcement follows a memo on February 22 from Assistant Secretary of Defense Jonathan Woodson to all of the branches of the military about what the military was seeing in PTSD treatment, expressing that “the greatest concern is the suspicion of the over-prescription of antipsychotic medications for PTSD.”

In it, he also points out that while antidepressant use had changed little between 2002 and 2009, the prescription rates for atypical antipsychotics increased by 10 times during that period, from 0.1% to 1%. The memo says AstraZeneca’s Seroquel was prescribed to 1.4% of the Army and 0.7% of the Marines in fiscal year 2010.

On April 10, the Army’s Office of the Surgeon General also issued a guidance memo for PTSD, including caution about antipsychotic drugs. “There are numerous concerns with potential long-term adverse health effects,” the memo said, “and these medications have shown disappointing results in clinical trials in the treatment of PTSD.”

Wynn and Benedik hope their efforts will lead to better treatments for PTSD in both combat veterans and civilians.

“For pharmaceuticals that show benefits in treating combat-related PTSD, the Department of Defense may work toward a new indication or change in labeling,” Wynn said.

Published results from the first trial are expected by 2016.



, , , , , ,

No comments yet.

Leave a Reply

GET HELP NOW!
  • This field is for validation purposes and should be left unchanged.
Latest Drug Injury News

Big Pharma under Fire for Kickbacks to Docs

Trust and honesty are the cornerstones to a doctor-patient relationship. With so many doctors receiving financial incentives to use certain medications or medical devices, patients need to know if money drives the decision making process. Doctors are required to disclose potential financial conflicts to each other at conferences, but there currently is no law forcing […]

Dietary Supplements Damage Liver

A recent study revealed a significant increase in liver damage related to dietary supplements. The study, conducted by a national network of liver specialists, found a 13% increase in serious liver damage over a 10 year span. Some of these patients required liver transplants and some have even died due to liver failure. Authors of […]

FDA Advisory Committee Supports Approval of Gilead’s HIV Reducing Drug

The pharmaceutical industry may be on the verge of one of the greatest breakthrough’s that this generation has ever seen.

U.S. Health Regulators Issue New Restrictions For Gilenya, Novartis AG’s’ Multiple Sclerosis Pill

In December 2011, the FDA issued a Drug Safety Communication concerning a patient with multiple sclerosis (MS) who died within 24 hours of taking the first dose of Gilenya (fingolimod).

Plavix Linked with Internal Bleeding

Ten more people have died from Plavix, which had proven to be no better than aspirin against stroke even though it costs around 100 times more.

Latest Medical Device Injury News

Report Raises Concerns Over Heart Defibrillator Leads

The Food and Drug Administration (FDA) has just announced that they received a report that a St. Jude Durata cardiac defibrillator lead conductor became externalized; meaning the wire carrying electricity from the heart defibrillator to the heart was exposed through its insulation, a potentially dangerous and life-threatening defect.

HeartSine Class 1 Defibrillator Recall

HeartSine sent out a letter to customers in September, warning that the defibrillators may intermittently turn on and off, eventually depleting the battery.

FDA Medical Device Approval Based On Little Evidence

More than half of the high-risk cardiovascular devices approved in the past decade had no supporting active control data.

St. Jude Medical Gets FDA Warning

St. Jude Medical Inc. said it received a FDA warning about manufacturing and quality-control problems at its Sylmar, California, plant.

Hospira Still Facing Manufacturing And Regulatory Issues

Hospira has sent out 11 device notifications so far in 2013, including recall and device corrections. The company also said it sent notices to customers about some of its infusion pumps that had to either be recalled, fixed or adjusted.